Cybin Inc. (CYBN)
USD 6.5
(-1.81%)
USD 6.5
(-1.81%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 302.02 Million CAD | 259.28% |
| 2022 | 84.06 Million CAD | -8.74% |
| 2021 | 92.11 Million CAD | 5283.52% |
| 2020 | 1.71 Million CAD | 0.0% |
| 2019 | 1.71 Million CAD | 318.97% |
| 2018 | 408.37 Thousand CAD | -10.48% |
| 2017 | 456.18 Thousand CAD | 2.96% |
| 2016 | 443.07 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 284.64 Million CAD | -5.75% |
| 2023 Q3 | 129.72 Million CAD | 125.11% |
| 2023 FY | 302.02 Million CAD | 259.28% |
| 2023 Q1 | 74.59 Million CAD | 38.39% |
| 2023 Q4 | 302.02 Million CAD | 132.82% |
| 2023 Q2 | 57.62 Million CAD | -22.74% |
| 2022 Q2 | 69.11 Million CAD | -7.34% |
| 2022 FY | 84.06 Million CAD | -8.74% |
| 2022 Q4 | 53.89 Million CAD | -11.2% |
| 2022 Q3 | 60.69 Million CAD | -12.18% |
| 2022 Q1 | 74.59 Million CAD | -11.27% |
| 2021 Q1 | 82.83 Million CAD | -10.07% |
| 2021 FY | 92.11 Million CAD | 5283.52% |
| 2021 Q4 | 84.06 Million CAD | -11.66% |
| 2021 Q3 | 95.16 Million CAD | -9.77% |
| 2021 Q2 | 105.46 Million CAD | 27.32% |
| 2020 FY | 1.71 Million CAD | 0.0% |
| 2020 Q3 | 61.25 Million CAD | 29125.19% |
| 2020 Q2 | 209.59 Thousand CAD | -97.64% |
| 2020 Q1 | 8.89 Million CAD | 0.0% |
| 2020 Q4 | 92.11 Million CAD | 50.38% |
| 2019 FY | 1.71 Million CAD | 318.97% |
| 2018 FY | 408.37 Thousand CAD | -10.48% |
| 2017 FY | 456.18 Thousand CAD | 2.96% |
| 2016 FY | 443.07 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 19.38 Million USD | -1458.346% |
| Armata Pharmaceuticals, Inc. | 109.96 Million USD | -174.656% |
| Actinium Pharmaceuticals, Inc. | 81.44 Million USD | -270.831% |
| Azitra, Inc. | 5.11 Million USD | -5804.092% |
| Can-Fite BioPharma Ltd. | 9.98 Million USD | -2923.556% |
| Chromocell Therapeutics Corporation | 96.39 Thousand USD | -313231.12% |
| Calidi Biotherapeutics, Inc. | 10.01 Million USD | -2914.502% |
| CEL-SCI Corporation | 30.52 Million USD | -889.323% |
| iBio, Inc. | 28.73 Million USD | -951.1% |
| Lineage Cell Therapeutics, Inc. | 101.01 Million USD | -198.976% |
| MAIA Biotechnology, Inc. | 7.56 Million USD | -3891.396% |
| Matinas BioPharma Holdings, Inc. | 65.57 Million USD | -360.555% |
| NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | -3243.181% |
| NanoViricides, Inc. | 12.82 Million USD | -2255.349% |
| Oragenics, Inc. | 4.96 Million USD | -5981.406% |
| BiomX Inc. | 58.15 Million USD | -419.332% |
| BiomX Inc. | 58.15 Million USD | -419.332% |
| Protalix BioTherapeutics, Inc. | 84.43 Million USD | -257.703% |
| Palatin Technologies, Inc. | 10.74 Million USD | -2711.539% |
| Scorpius Holdings, Inc. | 51.03 Million USD | -491.765% |
| Theriva Biologics, Inc. | 60.21 Million USD | -401.608% |